Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H17NO |
Molecular Weight | 179.2588 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(C)CC1=C(OC)C=CC=C1
InChI
InChIKey=OEHAYUOVELTAPG-UHFFFAOYSA-N
InChI=1S/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3
Molecular Formula | C11H17NO |
Molecular Weight | 179.2588 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Methoxyphenamine also known as 2-methoxy-N-methylamphetamine (OMMA), is a beta adrenergic receptor agonist nd is used as a bronchodilator to treat asthma, chronic obstructive pulmonary disease (COPD) and postinfectious cough. In addition, methoxyphenamine using is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094118 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6121608 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
157 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3625484 |
60.3 mg single, oral dose: 60.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHOXYPHENAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1315 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3625484 |
60.3 mg single, oral dose: 60.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHOXYPHENAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3625484 |
60.3 mg single, oral dose: 60.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHOXYPHENAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | yes (co-administration study) Comment: Coadministration of quinidine (CYP2D6 inhibitor) increased methoxyphenamine excretion in 32-h urine by 103%. |
PubMed
Title | Date | PubMed |
---|---|---|
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001 Apr |
|
Anti-inflammatory effect of methoxyphenamine compound in rat model of chronic obstructive pulmonary disease. | 2003 Dec |
|
Microchip-based liquid-liquid extraction for gas-chromatography analysis of amphetamine-type stimulants in urine. | 2006 Sep 29 |
|
Doping control analysis of methoxyphenamine using liquid chromatography-tandem mass spectrometry. | 2008 |
|
Induction of metamorphosis of pediveliger larvae of the mussel Mytilus galloprovincialis Lamarck, 1819 using neuroactive compounds, KCl, NH4Cl and organic solvents. | 2008 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4578811
Unknown
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1983067
It was revealed, that methoxyphenamine antagonizes the effects of histamine both in vivo and in vitro. In vitro studies indicate a noncompetitive antagonism. Histamine-induced contractions of the isolated guinea-pig ileum were antagonized by methoxyphenamine (10(-5) to 10(-3) M). The histamine log-concentration-response curve was shifted to the right in a parallel manner by methoxyphenamine (10(-5) to 10(-4) M), without depression of maximum responses. However, at higher concentrations, maximum responses were reduced. The slope of the Schild plot was significantly different from -1. The degree of the rightward shift of the concentration-response curves to histamine, produced by 10(-5) M of methoxyphenamine [3.90-(2.83, 4.97) fold], was not significantly different from that produced by 3 x 10(-9) M of mepyramine [4.60-(2.86, 6.52) fold]. Methoxyphenamine, at concentrations of 10(-5) to 3 x 10(-4) M, had no significant effect on responses of guinea-pig ilea to acetylcholine (10(-9) to 10(-5) M).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:30:26 GMT 2023
by
admin
on
Sat Dec 16 16:30:26 GMT 2023
|
Record UNII |
J3Z5SRI26Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
||
|
WHO-ATC |
R03CB02
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
||
|
WHO-VATC |
QR03CB02
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB13624
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
SUB08860MIG
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
100000081437
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL2010507
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
29704
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | RxNorm | ||
|
J3Z5SRI26Z
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
1755
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
93-30-1
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
C005157
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
DTXSID0023292
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
Methoxyphenamine
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
4117
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
137
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
m7341
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
134817
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
C83958
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY | |||
|
202-237-7
Created by
admin on Sat Dec 16 16:30:27 GMT 2023 , Edited by admin on Sat Dec 16 16:30:27 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |